Analysts reacted swiftly after the U.S. Food and Drug Administration signaled it expects a prospective, randomized, sham surgery-controlled Phase 3 trial for uniQure N.V.'s Huntington’s disease gene therapy candidate, AMT-130. The regulatory guidance, summarized in minutes from a Type A meeting with the agency, weakened hopes that the company could rely on more flexible approaches such as historical control comparisons to secure earlier approval.
In clinical research contexts, a sham-controlled trial assigns a control group to receive an inactive, simulated procedure designed to resemble the active intervention so that outcomes can be compared under double-blind conditions. The FDA’s apparent preference for such a design - rather than approvals based on natural history datasets - has immediate consequences for trial complexity, timelines, and ethical debates about invasive placebo procedures.
Brokerage responses
Mizuho Investors downgraded uniQure from Outperform to Neutral and cut its price target to $12 from $33. The firm said confidence in regulatory flexibility for AMT-130 decreased materially after reviewing the Type A meeting minutes. While Mizuho had acknowledged the possibility of a Phase 3 study, the bank had expected more regulatory latitude, including potential reliance on historical controls. Instead, the FDA "strongly" recommended a prospective sham-controlled study, which Mizuho described as difficult to execute and one that could raise ethical questions.
As a result, Mizuho pushed back its expected launch window for AMT-130 from 2028 to 2030 and sharply lowered its probability of success for the program to 15% from 65%. The firm left its unadjusted sales forecast intact but adjusted its valuation-based target: the $12 price objective reflects a risk-adjusted valuation attributing $6 to AMT-130 and $6 to estimated year-end 2026 cash.
Bank of America also moved to downgrade the stock, shifting to Sector Perform and trimming its target price to $11, characterizing the regulatory update as disappointing. BofA echoed the view that the FDA is unwilling to accept comparisons to natural history data as a basis for approval and instead favors a randomized, double-blind, sham-controlled study design. The bank noted that a Type B meeting to discuss trial design is anticipated in the second quarter of 2026.
Implications for ongoing programs and readouts
Both Mizuho and BofA said that data currently being generated in the ongoing Phase 1/2 program - including a planned four-year readout expected in the third quarter of 2026 - are unlikely to be sufficient to support approval given the FDA’s apparent stance favoring a prospective sham-controlled Phase 3.
BofA further flagged that uniQure’s broader pipeline remains at an early stage. The firm noted positive data in Fabry disease but reported that mid- and high-dose cohorts for that program are currently on pause. The SOD1-ALS study remains on hold following a serious adverse event. Data for the mesial temporal lobe epilepsy program are limited; an update for that program is also expected in the second quarter of 2026.
What this means going forward
The FDA’s apparent insistence on a prospectively randomized sham-controlled Phase 3 for AMT-130 raises practical and ethical challenges for trial execution and extends the timeline to potential approval. Analysts have already reflected this shift in expectations through lower ratings, reduced price targets, a much lower probability of success for the program, and later projected commercialization dates. Several upcoming data readouts and regulatory interactions in 2026 will be watched closely, but under the current regulatory posture those milestones are unlikely to substitute for a prospective randomized trial.
Note on terminology - A sham-controlled trial is a randomized clinical study in which the control arm receives an inactive, simulated procedure designed to mimic the active intervention, commonly used in trials where the experimental approach involves a surgical or device-based procedure.